Inmune Bio vs Lyell Immunopharma
Inmune Bio is the larger business, with $50,000 of revenue in fiscal 2025 against $36,000 for Lyell Immunopharma (1.4 times as much). Inmune Bio grew faster (257.1% against -41.0%). Inmune Bio kept more of each dollar of sales as profit: a net margin of -91866.0% against -762355.6%. Inmune Bio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Inmune BioINMB, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $50,000 | $36,000 |
| Revenue growth | 257.1% | -41.0% |
| Net income | −$45.9m | −$274m |
| Operating margin | -94766.0% | -748344.4% |
| Net margin | -91866.0% | -762355.6% |
| Return on equity | -165.2% | -87.0% |
| Free cash flow | −$23.6m | −$151m |
| Cash | $24.8m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 161 |
| Market value | $36.2m | $252m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |